The Efficacy and Safety of Empagliflozin in Elderly Patients with Type 2 Diabetes Mellitus Complicating Cardiorenal Syndromes Type II and IV
Evaluation of Empagliflozin in CRS
Abstract
Objectives: Cardiorenal syndrome (CRS) is a complex clinical condition, leading to a deterioration in both cardiac and renal functions. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a novel anti-diabetic drug, which also improves cardiac and renal functions. However, there is little research on the efficacy and safety of empagliflozin in elderly type 2 diabetes mellitus (T2DM) patients with CRS. We aimed to evaluate the efficacy and safety of empagliflozin in elderly patients with T2DM complicated by Type II and IV CRS.
Methods: A randomized, prospective study was conducted involving 200 elderly patients diagnosed with T2DM and CRS, admitted to the cardiovascular department of Fujian Provincial Governmental Hospital from January 2020 to January 2024. Patients were randomized into an experimental group (n=100) treated with empagliflozin 10mg/day and a control group (n=100) receiving standard care. Blood glucose, cardiac and renal function indicators, adverse reactions and major adverse cardiovascular events were compared between groups. T-tests, Mann-Whitney U tests, Wilcoxon signed-rank tests, and chi-square tests were performed appropriately.
Results: After one-year follow-up, patients in the experimental group showed significant improvements in fasting blood glucose, glycated hemoglobin, serum creatinine, urinary microalbumin, NT-proBNP, left ventricular ejection fraction, and left ventricular end-diastolic diameter compared to the control group (P<0.05). Empagliflozin also reduced the incidence of major adverse cardiovascular events, with a non-significant increase in adverse reactions such as urinary tract infections and genital infections.
Conclusion: Empagliflozin demonstrates efficacy in improving glycemic control and cardiorenal function in elderly T2DM patients with CRS. However, the drug's effect on biomarkers of acute myocardial injury and thrombosis requires further investigation. This study contributes to the growing body of evidence supporting the use of SGLT2 inhibitors in the management of CRS and emphasizes the need for larger-scale, long-term studies to confirm these findings.
References
2. Ajibowo AO, Okobi OE, Emore E, et al. Cardiorenal Syndrome: A Literature Review. Cureus. 2023. 15(7): e41252.
3. Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. Age Ageing.
2019. 48(6): 859-866.
4. Rangaswami J, B halla V, Blair J, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019. 139(16): e840-e878.
5. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [published correction appears in Lancet. 2013 Feb 2;381(9864):374]. Lancet. 2012;380(9854):1662-1673.
6. Drexler Y, Tremblay J, Mesa RA, et al. Associations Between Albuminuria and Mortality Among US Adults by Demographic and Comorbidity Factors. J Am Heart Assoc. 2023;12(21):e030773.
7. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161.
8. Chinese Medical Association Diabetes Branch. Guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition). Chinese Journal of Diabetes. 2018. 10(1): 4-67.
9. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J.2010. 31(6): 703-11.
10. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J P hysio l. 1931. 72(1): 49-61.
11. Wang J, Dai M, Cao Q, et al. Carotid baroreceptor stimulation suppresses ventricular fibrillation in canines with chronic heart failure. Basic Res Cardiol. 2019. 114(6): 41.
12. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019. 33(2): 363-382.
13. A bassi Z, Khoury EE, Karram T, et al. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022.（9）: 933215.
14. Zhang Liang, Guo Yutong, Liu Yue, et al. Research progress on the role of inflammatory cells in ventricular remodeling after myocardial infarction. Chinese Journal of Cardiology. 2022. 27(2): 192-195.
15. Chen Rijin, He Jiuming, He Xiaohong, et al. Application value of circulating miRNA-21, IL-6 and BNP in detecting heart failure. Chinese and Foreign Medical Research. 2021. 19(14): 104-106.
16. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974. 34(1): 29-34.
17. Nakamura K, Miyoshi T, Yoshida M, et al. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. Int J Mol Sci. 2022. 23(7): 3587.
18. Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review [published correction appears in J Am Coll Cardiol. 2020 Sep 22;76(12):1505. doi: 10.1016/j.jacc.2020.08.010]. J Am Coll Cardiol. 2020;75(4):422-434.
19. Patel KP, Katsurada K, Zheng H. Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys. C irc Res. 2022. 130(10): 1601-1617.
20. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019. 380(4): 347-357.
21. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017. 377(7): 644-657.
22. Z inman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015. 373(22):2117-28.
23. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020. 383(15): 1425-1435.
24. Schukraft S, Hullin R. Cardiorenal Crosstalk in Patients with Heart Failure[J]. Kidney and Dialysis, 2022, 2(3): 369-385.
25. Davies M J, Aroda V R, Collins B S, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes care, 2022, 45(11): 2753-2786.
26. Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress[J]. Cardiovascular research, 2021, 117(1): 74-84.
27. Garber A J, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary[J]. Endocrine Practice, 2020, 26(1): 107-139.
Copyright (c) 2025 Mugen Cao, Qiuyan Lin, Liling Lin, Wenjie Zhang, Lifeng Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.